UCB BIOSCIENCES, Inc. — Biomedical Watch V2

Traitements6programmes

Essais3liés

Publications8liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
doxecitine and doxribtimineThis is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.	Myopathies	Phase 2	À vérifier	United States, Israel, Spain	À vérifier
fenfluramineThe primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.	Épilepsie	Phase 3	À vérifier	United States, Belgium, Germany, Italy, United Kingdom	À vérifier
LacosamideEP0060 is a multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) Lacosamide (LCM) in pediatric subjects \>= 1 month to \< 17 years of age with epilepsy.	Épilepsie	Phase 2	À vérifier	United States, Hungary, Italy, Poland, Ukraine	À vérifier
LacosamideEP0060 is a multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) Lacosamide (LCM) in pediatric subjects \>= 1 month to \< 17 years of age with epilepsy.	Épilepsie	Phase 2	À vérifier	United States, Hungary, Italy, Poland, Ukraine	À vérifier
fenfluramineThe primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.	Épilepsie	Phase 3	À vérifier	United States, Belgium, Germany, Italy, United Kingdom	À vérifier
doxecitine and doxribtimineThis is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.	Myopathies	Phase 2	À vérifier	United States, Israel, Spain	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
doxecitine and doxribtimine	Myopathies	Phase 2	NCT03845712	An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency	COMPLETED
fenfluramine	Épilepsie	Phase 3	NCT06118255	ORCHID — A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome	ACTIVE_NOT_RECRUITING
Lacosamide	Épilepsie	Phase 2	NCT02710890	ASPIRE — Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.	COMPLETED

Publications

8

Molécule	Indication / population	Titre	Journal	Date
fenfluramine		Beyond seizures: proceedings of the ERN EpiCARE working group 18 on developmental and epileptic encephalopathies.	Epilepsy & behavior : E&B
fenfluramine		Comparative diagnostic accuracy of panic provocation tests: A meta-analysis.	Journal of psychiatric research
fenfluramine		Fenfluramine for seizures in Dravet syndrome and Lennox-Gastaut syndrome: Mechanisms, clinical evidence, safety, and practical integration.	Epilepsy & behavior reports
Lacosamide		Clinical drug-oriented design, synthesis, and pharmacological evaluation of novel dual-target antiepileptic hybrid molecules.	Bioorganic chemistry
Lacosamide		Lacosamide Use After Traumatic Brain Injury: A Scoping Review.	Cureus
Lacosamide		Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures.	Annals of the Child Neurology Society
Lacosamide		Lacosamide and Increased Fracture Risk: Need for More Study of Antiseizure Medications and Bone Health.	Neurology
Lacosamide		Fracture Risk With Lacosamide vs Levetiracetam Monotherapy in Adults With Epilepsy.	Neurology